Committee for Orphan Medicinal Products elects new chair and vice-chair
At its September 2012 meeting, the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) elected Professor Bruno Sepodes from Portugal as its chair and Ms Lesley Greene, a volunteer patient representative for Eurordis, as its vice-chair.
At its September 2012 meeting, the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) elected Professor Bruno Sepodes from Portugal as its chair and Ms Lesley Greene, a volunteer patient representative for Eurordis, as its vice-chair. Both have been elected for a three-year mandate.
Prof. Sepodes brings his academic experience as a research scientist in pharmacology, immunopharmacology and pharmacotoxicology to his role as chair of the COMP, a committee that has a long tradition in dealing with state-of-the-art pharmaceutical innovation. He first became a member of the COMP in 2008 following nomination by the European Commission on the recommendation of the Agency.
Ms Greene’s election continues another tradition of the COMP: since the establishment of the Committee in 2001, the vice-chair has always been a representative of a patient organisation. This highlights the importance the contribution of civil society to the work of the COMP.
COMP opinions
During its September 2012 meeting, the COMP adopted a total of 12 recommendations for orphan designation. One of these medicines is recombinant human lecithin cholesterol acyltransferase, intended for the treatment of lecithin cholesterol acyltransferase deficiency, an ultra-rare enzyme deficiency affecting around 60 patients in Europe. There are currently no satisfactory treatments available for these patients.
Orphan designation can be granted early in the development process to substances that are intended for diagnosis, prevention or treatment of life-threatening or very serious conditions that affect not more than 5 in 10,000 people in the European Union (EU) or that would not be developed without incentives.
For the full list of opinions adopted by the COMP during its September 2012 meeting, please see the COMP monthly report, published today.
The COMP's recommendations for these substances are sent to the European Commission for the adoption of a decision. Once an orphan designation has been granted, sponsors have access to certain incentives during the development of the medicine. For each medicine that has been granted an orphan designation by the European Commission, the Agency publishes a summary of the opinion on its website.
Systematic publication of agendas and minutes
In line with the plans of the Agency’s Executive Director Guido Rasi to publish the agendas and minutes of the scientific committees, the COMP will publish the minutes of its July 2012 meeting next week.
From now on, each meeting's minutes detail the outcome of the COMP monthly meeting and will be published systematically after their adoption at the following monthly meeting. The Committee will also start publishing its agendas every month, starting with its October 2012 meeting.
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance